<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Surg</journal-id><journal-title>BMC Surgery</journal-title><issn pub-type="epub">1471-2482</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17352805</article-id><article-id pub-id-type="pmc">1828149</article-id><article-id pub-id-type="publisher-id">1471-2482-7-3</article-id><article-id pub-id-type="doi">10.1186/1471-2482-7-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; <italic>DR</italic>ainage vs. (direct) <italic>OP</italic>eration (DROP-trial)</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>van der Gaag</surname><given-names>Niels A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>n.a.vandergaag@amc.uva.nl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>de Castro</surname><given-names>Steve MM</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stevedecastro@gmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Rauws</surname><given-names>Erik AJ</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>e.a.rauws@amc.uva.nl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Bruno</surname><given-names>Marco J</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>m.j.bruno@amc.uva.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>van Eijck</surname><given-names>Casper HJ</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>c.vaneijck@erasmusmc.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kuipers</surname><given-names>Ernst J</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>e.j.kuipers@erasmusmc.nl</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Gerritsen</surname><given-names>Josephus JGM</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>J.Gerritsen@ziekenhuis-mst.nl</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Rutten</surname><given-names>Jan-Paul</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>jrut@surgery.azm.nl</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Greve</surname><given-names>Jan Willem</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>JW.Greve@surgery.azm.nl</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Hesselink</surname><given-names>Erik J</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>ejhesselink@planet.nl</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Klinkenbijl</surname><given-names>Jean HG</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>Jklinkenbijl@alysis.nl</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Rinkes</surname><given-names>Inne HM Borel</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>i.h.m.borelrinkes@umcutrecht.nl</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Boerma</surname><given-names>Djamila</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>djamilaboerma@hotmail.com</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Bonsing</surname><given-names>Bert A</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>B.A.Bonsing@lumc.nl</email></contrib><contrib id="A15" contrib-type="author"><name><surname>van Laarhoven</surname><given-names>Cees J</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>c.v.laarhoven@elisabeth.nl</email></contrib><contrib id="A16" contrib-type="author"><name><surname>Kubben</surname><given-names>Frank JGM</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>kubbenf@mcrz.nl</email></contrib><contrib id="A17" contrib-type="author"><name><surname>van der Harst</surname><given-names>Erwin</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>harste@mcrz.nl</email></contrib><contrib id="A18" contrib-type="author"><name><surname>Sosef</surname><given-names>Meindert N</given-names></name><xref ref-type="aff" rid="I15">15</xref><email>meindert.sosef@planet.nl</email></contrib><contrib id="A19" contrib-type="author"><name><surname>Bosscha</surname><given-names>Koop</given-names></name><xref ref-type="aff" rid="I16">16</xref><email>k.bosscha@jbz.nl</email></contrib><contrib id="A20" contrib-type="author"><name><surname>de Hingh</surname><given-names>Ignace HJT</given-names></name><xref ref-type="aff" rid="I17">17</xref><email>Ignace.d.Hingh@catharina-ziekenhuis.nl</email></contrib><contrib id="A21" contrib-type="author"><name><surname>Th de Wit</surname><given-names>Laurens</given-names></name><xref ref-type="aff" rid="I18">18</xref><email>l.t.dewit@olvg.nl</email></contrib><contrib id="A22" contrib-type="author"><name><surname>van Delden</surname><given-names>Otto M</given-names></name><xref ref-type="aff" rid="I19">19</xref><email>o.m.vandelden@amc.uva.nl</email></contrib><contrib id="A23" contrib-type="author"><name><surname>Busch</surname><given-names>Olivier RC</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>o.r.busch@amc.uva.nl</email></contrib><contrib id="A24" contrib-type="author"><name><surname>van Gulik</surname><given-names>Thomas M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>t.m.vangulik@amc.uva.nl</email></contrib><contrib id="A25" contrib-type="author"><name><surname>Bossuyt</surname><given-names>Patrick MM</given-names></name><xref ref-type="aff" rid="I20">20</xref><email>P.M.Bossuyt@amc.uva.nl</email></contrib><contrib id="A26" contrib-type="author"><name><surname>Gouma</surname><given-names>Dirk J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>d.j.gouma@amc.uva.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Surgery, Academic Medical Center Amsterdam, the Netherlands</aff><aff id="I2"><label>2</label>Department of Gastroenterology, Amsterdam, the Netherlands</aff><aff id="I3"><label>3</label>Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands</aff><aff id="I4"><label>4</label>Department of Gastroenterology, Erasmus Medical Center, Rotterdam, the Netherlands</aff><aff id="I5"><label>5</label>Department of Surgery, Medical Spectrum Twente, Enschede, the Netherlands</aff><aff id="I6"><label>6</label>Department of Surgery, University Hospital Maastricht, Maastricht, the Netherlands</aff><aff id="I7"><label>7</label>Department of Surgery, Gelre Hospital, Apeldoorn, the Netherlands</aff><aff id="I8"><label>8</label>Department of Surgery, Rijnstate Hospital, Arnhem, the Netherlands</aff><aff id="I9"><label>9</label>Department of Surgery, University Medical Center Utrecht, the Netherlands</aff><aff id="I10"><label>10</label>Department of Surgery, St Antonius Hospital, Nieuwegein, the Netherlands</aff><aff id="I11"><label>11</label>Department of Surgery, Leiden University Medical Center, the Netherlands</aff><aff id="I12"><label>12</label>Department of Surgery, St Elisabeth Hospital, Tilburg, the Netherlands</aff><aff id="I13"><label>13</label>Department of Gastroenterology, Medical Center Rijnmond Zuid, Rotterdam, the Netherlands</aff><aff id="I14"><label>14</label>Department of Surgery, Medical Center Rijnmond Zuid, Rotterdam, the Netherlands</aff><aff id="I15"><label>15</label>Department of Surgery, Atrium Medical Center, Heerlen, the Netherlands</aff><aff id="I16"><label>16</label>Department of Surgery, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands</aff><aff id="I17"><label>17</label>Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands</aff><aff id="I18"><label>18</label>Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands</aff><aff id="I19"><label>19</label>Department of Radiology, Academic Medical Center Amsterdam, The Netherlands</aff><aff id="I20"><label>20</label>Department of clinical epidemiology and biostatistics, Academic Medical Center Amsterdam, the Netherlands</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>12</day><month>3</month><year>2007</year></pub-date><volume>7</volume><fpage>3</fpage><lpage>3</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2482/7/3"></ext-link><history><date date-type="received"><day>15</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>Copyright Â© 2007 van der Gaag et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>van der Gaag et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="9624" xml_f="9634" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="9645" xml_f="10663" txt_i="22" txt_f="1040">Surgery in patients with obstructive jaundice caused by a periampullary (pancreas, papilla, distal bile duct) tumor is associated with a higher risk of postoperative complications than in non-jaundiced patients. Preoperative biliary drainage was introduced in an attempt to improve the general condition and thus reduce postoperative morbidity and mortality. Early studies showed a reduction in morbidity. However, more recently the focus has shifted towards the negative effects of drainage, such as an increase of infectious complications. Whether biliary drainage should always be performed in jaundiced patients remains controversial. The randomized controlled multicenter DROP-trial (DRainage vs. Operation) was conceived to compare the outcome of a 'preoperative biliary drainage strategy' (standard strategy) with that of an 'early-surgery' strategy, with respect to the incidence of severe complications (primary-outcome measure), hospital stay, number of invasive diagnostic tests, costs, and quality of life.</offsets></p></sec><sec><title><offsets xml_i="10685" xml_f="10699" txt_i="1042" txt_f="1056">Methods/design</offsets></title><p><offsets xml_i="10710" xml_f="11800" txt_i="1057" txt_f="2147">Patients with obstructive jaundice due to a periampullary tumor, eligible for exploration after staging with CT scan, and scheduled to undergo a "curative" resection, will be randomized to either "early surgical treatment" (within one week) or "preoperative biliary drainage" (for 4 weeks) and subsequent surgical treatment (standard treatment). Primary outcome measure is the percentage of severe complications up to 90 days after surgery. The sample size calculation is based on the equivalence design for the primary outcome measure. If equivalence is found, the comparison of the secondary outcomes will be essential in selecting the preferred strategy. Based on a 40% complication rate for early surgical treatment and 48% for preoperative drainage, equivalence is taken to be demonstrated if the percentage of severe complications with early surgical treatment is not more than 10% higher compared to standard treatment: preoperative biliary drainage. Accounting for a 10% dropout, 105 patients are needed in each arm resulting in a study population of 210 (alpha = 0.95, beta = 0.8).</offsets></p></sec><sec><title><offsets xml_i="11822" xml_f="11832" txt_i="2149" txt_f="2159">Discussion</offsets></title><p><offsets xml_i="11843" xml_f="12061" txt_i="2160" txt_f="2378">The DROP-trial is a randomized controlled multicenter trial that will provide evidence whether or not preoperative biliary drainage is to be performed in patients with obstructive jaundice due to a periampullary tumor.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="12123" xml_f="12133" txt_i="2387" txt_f="2397">Background</offsets></title><p><offsets xml_i="12144" xml_f="12429" txt_i="2398" txt_f="2683">Patients with obstructive jaundice caused by a tumor in the pancreatic head area (pancreas, distal bile duct, papilla of Vater), without radiological evidence of irresectability, will undergo an exploration with the intention of resection of the tumor, being the only option for cure [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="12460" xml_f="12461" txt_i="2683" txt_f="2684">1</offsets></xref><offsets xml_i="12468" xml_f="12469" txt_i="2684" txt_f="2685">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="12500" xml_f="12501" txt_i="2685" txt_f="2686">4</offsets></xref><offsets xml_i="12508" xml_f="12654" txt_i="2686" txt_f="2832">]. If a resection is not possible due to locoregional irresectability or distant metastases, a biliary and gastric bypass procedure is performed [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="12685" xml_f="12686" txt_i="2832" txt_f="2833">5</offsets></xref><offsets xml_i="12693" xml_f="12694" txt_i="2833" txt_f="2834">-</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="12725" xml_f="12726" txt_i="2834" txt_f="2835">8</offsets></xref><offsets xml_i="12733" xml_f="12920" txt_i="2835" txt_f="3022">]. Surgery in jaundiced patients with a tumor in the pancreatic head area is associated with a higher risk of postoperative complications compared with surgery in non jaundiced patients [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="12951" xml_f="12952" txt_i="3022" txt_f="3023">9</offsets></xref><offsets xml_i="12959" xml_f="12960" txt_i="3023" txt_f="3024">-</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="12992" xml_f="12994" txt_i="3024" txt_f="3026">11</offsets></xref><offsets xml_i="13001" xml_f="13558" txt_i="3026" txt_f="3583">]. These complications primarily consist of septic complications (cholangitis, abscesses, and leakage), haemorrhage, impaired wound healing and renal disorders. The increased risk of surgery in jaundiced patients was recognized already in 1935 by Allen O. Whipple, who proposed a two staged procedure for surgery in deeply jaundiced patients. The first stage consisted of a drainage procedure by a cholecystogastrostomy, to decompress the biliary tract in order to restore normal liver function, followed four weeks later by radical resection of the tumor [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13590" xml_f="13592" txt_i="3583" txt_f="3585">12</offsets></xref><offsets xml_i="13599" xml_f="13792" txt_i="3585" txt_f="3778">]. Numerous experimental and clinical studies have been performed since, investigating the cause and directed at prevention of complications after surgery in patients with obstructive jaundice.</offsets></p><p><offsets xml_i="13799" xml_f="14008" txt_i="3779" txt_f="3988">While the postoperative mortality rate after pancreatoduodenectomy has been reduced from around 20% to 1â5% in experienced centres, the morbidity rate has remained virtually unchanged, ranging from 40 to 60% [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="14039" xml_f="14040" txt_i="3988" txt_f="3989">5</offsets></xref><offsets xml_i="14047" xml_f="14048" txt_i="3989" txt_f="3990">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="14079" xml_f="14080" txt_i="3990" txt_f="3991">6</offsets></xref><offsets xml_i="14087" xml_f="14088" txt_i="3991" txt_f="3992">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="14119" xml_f="14120" txt_i="3992" txt_f="3993">8</offsets></xref><offsets xml_i="14127" xml_f="14128" txt_i="3993" txt_f="3994">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="14159" xml_f="14160" txt_i="3994" txt_f="3995">9</offsets></xref><offsets xml_i="14167" xml_f="14513" txt_i="3995" txt_f="4341">]. Many different etiologic factors for development of complications have been characterized: presence of toxic substances as bilirubin and bile salts, impaired nutritional status, effects of endotoxins, bacterial translocation, modulation of the inflammatory cascade with cytokine release, reduction of cellular immunity and nutritional status [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="14545" xml_f="14547" txt_i="4341" txt_f="4343">13</offsets></xref><offsets xml_i="14554" xml_f="14555" txt_i="4343" txt_f="4344">-</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="14587" xml_f="14589" txt_i="4344" txt_f="4346">21</offsets></xref><offsets xml_i="14596" xml_f="14819" txt_i="4346" txt_f="4569">]. For these etiologic factors different interventions have been undertaken in the past decades, attempting to lower the risk of complications. The current project addresses the issue of preoperative biliary drainage (PBD).</offsets></p><p><offsets xml_i="14826" xml_f="15038" txt_i="4570" txt_f="4782">Early studies on external PBD could not demonstrate a reduction in complication rate in humans because this procedure, although relieving the biliary obstruction, does not restore the bile flow to the gut lumen [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="15070" xml_f="15072" txt_i="4782" txt_f="4784">22</offsets></xref><offsets xml_i="15079" xml_f="15295" txt_i="4784" txt_f="5000">]. Internal drainage has been shown in multiple experimental models to improve liver function and nutritional status, to reduce systemic endotoxemia and cytokine release, and subsequently to improve immune response [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="15327" xml_f="15329" txt_i="5000" txt_f="5002">13</offsets></xref><offsets xml_i="15336" xml_f="15337" txt_i="5002" txt_f="5003">-</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="15369" xml_f="15371" txt_i="5003" txt_f="5005">15</offsets></xref><offsets xml_i="15378" xml_f="15379" txt_i="5005" txt_f="5006">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="15411" xml_f="15413" txt_i="5006" txt_f="5008">19</offsets></xref><offsets xml_i="15420" xml_f="15421" txt_i="5008" txt_f="5009">-</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="15453" xml_f="15455" txt_i="5009" txt_f="5011">21</offsets></xref><offsets xml_i="15462" xml_f="15536" txt_i="5011" txt_f="5085">]. Finally the mortality was significantly reduced in these animal models[</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="15568" xml_f="15570" txt_i="5085" txt_f="5087">16</offsets></xref><offsets xml_i="15577" xml_f="15695" txt_i="5087" txt_f="5205">]. The first non-randomized studies on internal PBD in jaundiced patients reported a reduced mortality and morbidity [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="15727" xml_f="15729" txt_i="5205" txt_f="5207">22</offsets></xref><offsets xml_i="15736" xml_f="15859" txt_i="5207" txt_f="5330">]. However, clinical studies and small randomized trials could not confirm the positive effect of PBD on surgical outcome [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="15891" xml_f="15893" txt_i="5330" txt_f="5332">23</offsets></xref><offsets xml_i="15900" xml_f="15901" txt_i="5332" txt_f="5333">-</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="15933" xml_f="15935" txt_i="5333" txt_f="5335">27</offsets></xref><offsets xml_i="15942" xml_f="16062" txt_i="5335" txt_f="5455">]. Some studies even reported a deleterious effect, partly due to complications associated with the drainage procedure [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="16094" xml_f="16096" txt_i="5455" txt_f="5457">28</offsets></xref><offsets xml_i="16103" xml_f="16104" txt_i="5457" txt_f="5458">-</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="16136" xml_f="16138" txt_i="5458" txt_f="5460">32</offsets></xref><offsets xml_i="16145" xml_f="16360" txt_i="5460" txt_f="5675">]. Despite these results, PBD is generally accepted in The Netherlands. In previous studies we found that around 90% of patients with obstructive jaundice currently undergo preoperative drainage in The Netherlands [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="16392" xml_f="16394" txt_i="5675" txt_f="5677">28</offsets></xref><offsets xml_i="16401" xml_f="16402" txt_i="5677" txt_f="5678">,</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="16434" xml_f="16436" txt_i="5678" txt_f="5680">29</offsets></xref><offsets xml_i="16443" xml_f="16960" txt_i="5680" txt_f="6197">]. The dominance of drainage can be attributed in part to the familiarity of endoscopic retrograde cholangiopancreatography (ERCP), which has been used in the past as the first diagnostic procedure for obstructive jaundice. The time needed for extensive diagnostic workup, including diagnostic laparoscopy (DL), is a logistic explanation for the assumed benefit of PBD. However, the value of DL for periampullary tumors is disputed, especially in the light of improvement of other non-invasive diagnostic procedures [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="16991" xml_f="16992" txt_i="6197" txt_f="6198">1</offsets></xref><offsets xml_i="16999" xml_f="17000" txt_i="6198" txt_f="6199">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="17031" xml_f="17032" txt_i="6199" txt_f="6200">4</offsets></xref><offsets xml_i="17039" xml_f="17040" txt_i="6200" txt_f="6201">,</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="17072" xml_f="17074" txt_i="6201" txt_f="6203">33</offsets></xref><offsets xml_i="17081" xml_f="17082" txt_i="6203" txt_f="6204">,</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="17114" xml_f="17116" txt_i="6204" txt_f="6206">34</offsets></xref><offsets xml_i="17123" xml_f="17381" txt_i="6206" txt_f="6464">]. Other important factors that influence the decision to opt for PBD are (local) referral patterns and waiting lists. Current state-of-the-art radiological diagnostic and staging procedures for suspected periampullary tumors require only a minimum of time [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="17412" xml_f="17413" txt_i="6464" txt_f="6465">1</offsets></xref><offsets xml_i="17420" xml_f="17644" txt_i="6465" txt_f="6689">]. These non-invasive radiological procedures have the same diagnostic accuracy as ERCP, an invasive diagnostic procedure, and, moreover, offer the advantage of assessing local tumor extension as well as distant metastases [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="17675" xml_f="17676" txt_i="6689" txt_f="6690">1</offsets></xref><offsets xml_i="17683" xml_f="17684" txt_i="6690" txt_f="6691">-</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="17715" xml_f="17716" txt_i="6691" txt_f="6692">3</offsets></xref><offsets xml_i="17723" xml_f="17818" txt_i="6692" txt_f="6787">]. Therefore, ERCP with subsequent drainage as part of a routine diagnostic workup is outdated.</offsets></p><p><offsets xml_i="17825" xml_f="18156" txt_i="6788" txt_f="7119">ERCP and endoscopic sphincterotomy with insertion of biliary and pancreatic stents is a difficult gastrointestinal endoscopic procedure. Complications, such as haemorrhage, pancreatitis, perforation of the duodenal wall, cholangitis and stent occlusion cannot always be avoided and occur in approximately 10 percent of procedures [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="18188" xml_f="18190" txt_i="7119" txt_f="7121">35</offsets></xref><offsets xml_i="18197" xml_f="18198" txt_i="7121" txt_f="7122">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="18230" xml_f="18232" txt_i="7122" txt_f="7124">36</offsets></xref><offsets xml_i="18239" xml_f="18323" txt_i="7124" txt_f="7208">]. Mortality as a consequence of the procedure is reported in 0.5%â1% of the cases [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="18355" xml_f="18357" txt_i="7208" txt_f="7210">36</offsets></xref><offsets xml_i="18364" xml_f="18520" txt_i="7210" txt_f="7366">]. The negative side-effects of PBD, such as an increase of infectious complications after surgery, has been the focus of attention in more recent studies [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="18552" xml_f="18554" txt_i="7366" txt_f="7368">30</offsets></xref><offsets xml_i="18561" xml_f="18562" txt_i="7368" txt_f="7369">-</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="18594" xml_f="18596" txt_i="7369" txt_f="7371">32</offsets></xref><offsets xml_i="18603" xml_f="18717" txt_i="7371" txt_f="7485">]. It was concluded that the potential advantages of preoperative drainage fail to outweigh the negative effects [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="18749" xml_f="18751" txt_i="7485" txt_f="7487">20</offsets></xref><offsets xml_i="18758" xml_f="18759" txt_i="7487" txt_f="7488">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="18791" xml_f="18793" txt_i="7488" txt_f="7490">23</offsets></xref><offsets xml_i="18800" xml_f="18801" txt_i="7490" txt_f="7491">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="18833" xml_f="18835" txt_i="7491" txt_f="7493">24</offsets></xref><offsets xml_i="18842" xml_f="18843" txt_i="7493" txt_f="7494">,</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="18875" xml_f="18877" txt_i="7494" txt_f="7496">28</offsets></xref><offsets xml_i="18884" xml_f="18885" txt_i="7496" txt_f="7497">-</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="18917" xml_f="18919" txt_i="7497" txt_f="7499">32</offsets></xref><offsets xml_i="18926" xml_f="18928" txt_i="7499" txt_f="7501">].</offsets></p><p><offsets xml_i="18935" xml_f="19070" txt_i="7502" txt_f="7637">In the light of the ongoing controversy of PBD, a meta-analysis of randomized clinical trials and comparative studies was carried out [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="19102" xml_f="19104" txt_i="7637" txt_f="7639">37</offsets></xref><offsets xml_i="19111" xml_f="20240" txt_i="7639" txt_f="8768">]. The aim of this study was to evaluate the efficacy of drainage in jaundiced patients compared with patients that underwent direct surgical treatment. No difference in mortality could be detected between both strategies, but overall complication rate in patients that underwent PBD was significantly higher compared with direct surgical treatment, 57.3% and 41.9% respectively (level I evidence). The mean overall hospital stay was increased by two weeks in patients that underwent biliary drainage. Unfortunately, most of the studies have methodological flaws (e.g. differences in drainage procedures, duration of drainage, internal vs. external drainage, surgical procedures, small sample size) and do not provide unequivocal treatment recommendations. Therefore, a prospective randomized trial addressing the effects of PBD is indicated. Especially, for the potential consequences of future treatment might be considerable; a shorter workup period, less invasive diagnostic procedures (ERCP) and a shorter time interval to surgery. The study focuses on complication rate (40â60%), the primary endpoint for most past studies.</offsets></p></sec><sec><title><offsets xml_i="20262" xml_f="20276" txt_i="8770" txt_f="8784">Methods/Design</offsets></title><sec><title><offsets xml_i="20296" xml_f="20312" txt_i="8785" txt_f="8801">Study objectives</offsets></title><p><offsets xml_i="20323" xml_f="20657" txt_i="8802" txt_f="9136">The proposed project involves a randomized multicenter trial to compare the outcome of "a preoperative biliary drainage strategy" (standard strategy) with that of an "early surgery" strategy, with respect to the incidence of severe complications (primary outcome measure), hospital stay, number of invasive diagnostic tests and costs.</offsets></p></sec><sec><title><offsets xml_i="20679" xml_f="20691" txt_i="9138" txt_f="9150">Study design</offsets></title><p><offsets xml_i="20702" xml_f="21235" txt_i="9151" txt_f="9684">The DROP-trial is a randomized multicenter trial with four academic and ten regional hospitals participating in the project. Patients with obstructive jaundice (bilirubin level 40â250 Î¼mol/l) due to a pancreatic/periampullary tumor, who are candidate for exploration after staging with CT scan, and scheduled to undergo a "curative" resection, will be randomized to either "early surgical treatment" (within one week) or "preoperative biliary drainage" (for four weeks) and subsequent surgical treatment (standard treatment) (figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="21265" xml_f="21266" txt_i="9684" txt_f="9685">1</offsets></xref><offsets xml_i="21273" xml_f="21423" txt_i="9685" txt_f="9835">). Randomization is centralized in the Academic Medical Center, Amsterdam, by means of a computer generated allocation with stratification for center.</offsets></p><fig position="float" id="F1"><label><offsets xml_i="21464" xml_f="21472" txt_i="9836" txt_f="9844">Figure 1</offsets></label><caption><p><offsets xml_i="21492" xml_f="21513" txt_i="9844" txt_f="9865">DROP-study flowchart.</offsets></p></caption><graphic xlink:href="1471-2482-7-3-1"></graphic></fig></sec><sec><title><offsets xml_i="21599" xml_f="21615" txt_i="9867" txt_f="9883">Study population</offsets></title><p><offsets xml_i="21626" xml_f="22602" txt_i="9884" txt_f="10848">The study population consists of patients with the clinical diagnosis of obstructive jaundice due to a pancreatic head or periampullary tumor. Inclusion criteria are; a serum bilirubin level of &gt; 40 Î¼mol/l and &lt; 250 Î¼mol/l at randomization, CT without evidence of distant metastases or local tumor ingrowth into portal or mesenteric vessels (as defined by the tumor surrounding the vessel for at least 180 degrees of the circumference), referred for surgical treatment to one of the participating centres, time between CT and randomization â¤ 4 days, informed consent. Exclusion criteria are; age &gt; 85 years or severe co-morbidity (Karnofsky &lt;50%) and other contraindications for major surgery, cholangitis/infection, previous ERCP and stenting or percutaneous biliary drainage, previous chemotherapy for this malignancy, severe gastric outlet obstruction (stenosis duodenum due to tumor ingrowth) defined as vomiting, nausea and/or oral intake less than one l/day.</offsets></p></sec><sec><title><offsets xml_i="22624" xml_f="22649" txt_i="10850" txt_f="10875">Primary outcome parameter</offsets></title><p><offsets xml_i="22660" xml_f="23127" txt_i="10876" txt_f="11340">Primary outcome parameter are severe complications and the study is designed for detecting equivalence in the occurrence of these events during treatment within 120 days after randomization. This will include at least 90 days follow-up after surgery, a period selected as adequate, while &gt; 95% of complications will occur within 30 days after surgery. A longer observation period up to one year will potentially include effects of progressive or recurrent disease.</offsets></p><p><offsets xml_i="23134" xml_f="23447" txt_i="11341" txt_f="11654">A severe complication is defined as any complication, related to the drainage procedure and surgical treatment, leading to an additional invasive intervention or relaparotomy with subsequent prolonged hospital stay or death, or readmission for disease related morbidity within 120 days after randomization (table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="23479" xml_f="23480" txt_i="11654" txt_f="11655">1</offsets></xref><offsets xml_i="23487" xml_f="23700" txt_i="11655" txt_f="11868">). The definition of all these complications, as well as their management, have been extensively evaluated in previous studies in our institution during the past 10 years according to generally accepted criteria [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="23731" xml_f="23732" txt_i="11868" txt_f="11869">5</offsets></xref><offsets xml_i="23739" xml_f="23740" txt_i="11869" txt_f="11870">,</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="23772" xml_f="23774" txt_i="11870" txt_f="11872">28</offsets></xref><offsets xml_i="23781" xml_f="23782" txt_i="11872" txt_f="11873">,</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="23814" xml_f="23816" txt_i="11873" txt_f="11875">29</offsets></xref><offsets xml_i="23823" xml_f="23824" txt_i="11875" txt_f="11876">,</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="23856" xml_f="23858" txt_i="11876" txt_f="11878">35</offsets></xref><offsets xml_i="23865" xml_f="23866" txt_i="11878" txt_f="11879">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="23898" xml_f="23900" txt_i="11879" txt_f="11881">36</offsets></xref><offsets xml_i="23907" xml_f="23908" txt_i="11881" txt_f="11882">,</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="23940" xml_f="23942" txt_i="11882" txt_f="11884">38</offsets></xref><offsets xml_i="23949" xml_f="23950" txt_i="11884" txt_f="11885">,</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="23982" xml_f="23984" txt_i="11885" txt_f="11887">39</offsets></xref><offsets xml_i="23991" xml_f="23993" txt_i="11887" txt_f="11889">].</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="24041" xml_f="24048" txt_i="11890" txt_f="11897">Table 1</offsets></label><caption><p><offsets xml_i="24068" xml_f="24159" txt_i="11897" txt_f="11988">Severe ERCP- and surgery-related (postoperative) complications [5,28,29,35,36,38,39,43,44].</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold><italic><offsets xml_i="24261" xml_f="24273" txt_i="11990" txt_f="12002">COMPLICATION</offsets></italic></bold></td><td align="left"><bold><italic><offsets xml_i="24325" xml_f="24333" txt_i="12003" txt_f="12011">CRITERIA</offsets></italic></bold></td></tr></thead><tbody><tr><td align="left"><bold><italic><offsets xml_i="24409" xml_f="24413" txt_i="12012" txt_f="12016">ERCP</offsets></italic></bold></td><td></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="24487" xml_f="24507" txt_i="12020" txt_f="12040">- Acute pancreatitis</offsets></td><td align="left"><offsets xml_i="24529" xml_f="24709" txt_i="12041" txt_f="12221">Abdominal pain and a serum concentration of pancreatic enzymes (amylase or lipase) two or more times the upper limit of normal, that required more than one night of hospitalisation</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="24749" xml_f="24762" txt_i="12223" txt_f="12236">- Cholangitis</offsets></td><td align="left"><offsets xml_i="24784" xml_f="24916" txt_i="12237" txt_f="12369">Elevation in the temperature to more than 38Â°C, thought to have a biliary cause, without concomitant evidence of acute cholecystitis</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="24956" xml_f="24977" txt_i="12371" txt_f="12392">- Acute cholecystitis</offsets></td><td align="left"><offsets xml_i="24999" xml_f="25145" txt_i="12393" txt_f="12539">No suggestive clinical or radiographic signs of acute cholecystitis before the procedure and if emergency cholecystectomy is subsequently required</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="25185" xml_f="25198" txt_i="12541" txt_f="12554">- Perforation</offsets></td><td align="left"><offsets xml_i="25220" xml_f="25302" txt_i="12555" txt_f="12637">Retroperitoneal or bowel-wall perforation documented by any radiographic technique</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="25342" xml_f="25355" txt_i="12639" txt_f="12652">- Haemorrhage</offsets></td><td align="left"><offsets xml_i="25377" xml_f="25558" txt_i="12653" txt_f="12834">Clinical evidence of bleeding (melena or hematemesis) with an associated decrease of at least 2 g per decilitre in the haemoglobin concentration, or the need for a blood transfusion</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="25598" xml_f="25615" txt_i="12836" txt_f="12853">- Stent Occlusion</offsets></td><td align="left"><offsets xml_i="25637" xml_f="25700" txt_i="12854" txt_f="12917">Recurring obstructive jaundice with necessary stent replacement</offsets></td></tr><tr><td align="left"><bold><italic><offsets xml_i="25745" xml_f="25752" txt_i="12918" txt_f="12925">SURGERY</offsets></italic></bold></td><td></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="25826" xml_f="25856" txt_i="12929" txt_f="12959">- Pancreatojejunostomy leakage</offsets></td><td align="left"><offsets xml_i="25878" xml_f="26087" txt_i="12960" txt_f="13169">Drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase activity, graded according to clinical course (ISGPS grade A, B, C)</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="26127" xml_f="26159" txt_i="13171" txt_f="13203">- Postpancreatectomy haemorrhage</offsets></td><td align="left"><offsets xml_i="26181" xml_f="26295" txt_i="13204" txt_f="13318">Bleeding after the index operation requiring â¥ 4 units of packed cells and/or leading to relaparotomy/intervention</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="26335" xml_f="26361" txt_i="13320" txt_f="13346">- Delayed gastric emptying</offsets></td><td align="left"><offsets xml_i="26383" xml_f="26549" txt_i="13347" txt_f="13513">Gastric stasis requiring nasogastric intubation for 10 days or more, or the inability to tolerate a regular (solid) diet on or before the fourteenth postoperative day</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="26589" xml_f="26606" txt_i="13515" txt_f="13532">- Biliary leakage</offsets></td><td align="left"><offsets xml_i="26628" xml_f="26690" txt_i="13533" txt_f="13595">Bilirubin in abdominal drain or dehiscence found at laparotomy</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="26730" xml_f="26738" txt_i="13597" txt_f="13605">- Sepsis</offsets></td><td align="left"><offsets xml_i="26760" xml_f="26914" txt_i="13606" txt_f="13760">Presence of two or more of the following: fever or hypothermia, leucocytosis or leucopenia, tachycardia, and tachypnea or a supernormal minute ventilation</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="26954" xml_f="26989" txt_i="13762" txt_f="13797">- Intra-abdominal abscess formation</offsets></td><td align="left"><offsets xml_i="27011" xml_f="27189" txt_i="13798" txt_f="13976">Intra-abdominal fluid collection with positive cultures identified by ultrasonography or computed tomography, associated with persistent fever and elevations of white blood cells</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="27229" xml_f="27246" txt_i="13978" txt_f="13995">- Wound infection</offsets></td><td align="left"><offsets xml_i="27268" xml_f="27374" txt_i="13996" txt_f="14102">Requiring intervention with subsequent prolonged hospital stay, otherwise considered as minor complication</offsets></td></tr><tr><td></td><td align="left"><offsets xml_i="27414" xml_f="27429" txt_i="14104" txt_f="14119">- Burst abdomen</offsets></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="27478" xml_f="27514" txt_i="14122" txt_f="14158">- Any relaparotomy for other reasons</offsets></td><td></td></tr><tr><td></td><td align="left"><offsets xml_i="27563" xml_f="27574" txt_i="14161" txt_f="14172">- Pneumonia</offsets></td><td></td></tr></tbody></table></table-wrap><p><offsets xml_i="27625" xml_f="27891" txt_i="14174" txt_f="14440">To exclude bias in determining events of the primary endpoint, a blinded adjunction committee will review all events and evaluate whether events account as severe complications (with intervention, relaparotomy) needing prolonged hospital stay, or even a readmission.</offsets></p></sec><sec><title><offsets xml_i="27913" xml_f="27941" txt_i="14442" txt_f="14470">Secondary outcome parameters</offsets></title><p><offsets xml_i="27952" xml_f="28381" txt_i="14471" txt_f="14900">Secondary endpoints are hospital stay, the number of (invasive) diagnostic procedures, medical and non medical costs, and quality of life. Quality of life will be measured for patients treated at the trial centre, at fixed intervals, by two validated questionnaires; the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C-30 (QLQ-C30) and its Pancreatic Cancer Module (QLQ-PAN26) [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="28413" xml_f="28415" txt_i="14900" txt_f="14902">40</offsets></xref><offsets xml_i="28422" xml_f="28424" txt_i="14902" txt_f="14904">].</offsets></p></sec><sec><title><offsets xml_i="28446" xml_f="28467" txt_i="14906" txt_f="14927">Participating centres</offsets></title><p><offsets xml_i="28478" xml_f="28632" txt_i="14928" txt_f="15082">Fourteen Dutch hospitals of the DROP-Trial group, including four academic centres and ten non-academic centres, are currently participating in this trial.</offsets></p></sec><sec><title><offsets xml_i="28654" xml_f="28660" txt_i="15084" txt_f="15090">Ethics</offsets></title><p><offsets xml_i="28671" xml_f="28992" txt_i="15091" txt_f="15412">This study is conducted in accordance with the principles of the Declaration of Helsinki and 'good clinical practice' guidelines. The independent medical ethics committees of the participating hospitals have approved the study protocol. Prior to randomization, written informed consent will be obtained from all patients.</offsets></p></sec><sec><title><offsets xml_i="29014" xml_f="29027" txt_i="15414" txt_f="15427">Study outline</offsets></title><p><offsets xml_i="29038" xml_f="29582" txt_i="15428" txt_f="15972">Patients may be included if CT scan has demonstrated a lesion in the pancreatic head area without metastases and/or local tumor ingrowth. Local physicians/gastroenterologists can refer patients for the study by contacting the primary trial centre or one of the participating centres (see addendum 1). Written informed consent will be obtained at the outpatient department according to the Guidelines of Clinical Research in Humans, when the patient meets the in- and exclusion criteria. Randomization is performed instantly by the trial centre.</offsets></p><p><offsets xml_i="29589" xml_f="29991" txt_i="15973" txt_f="16375">After randomization, patients will be scheduled, either for surgical treatment within one week, or PBD with subsequent surgical treatment after four weeks. PBD is preferably performed by local gastroenterologists or in the referral centre according to local policy. The participating centres accepted to arrange extra operating room capacity to guarantee early surgery to be carried out when indicated.</offsets></p><sec><title><offsets xml_i="30007" xml_f="30017" txt_i="16376" txt_f="16386">ERCP + PBD</offsets></title><p><offsets xml_i="30028" xml_f="30145" txt_i="16387" txt_f="16504">- ERCP with stent placement will be performed by an experienced endoscopist, by insertion of a single (plastic) stent</offsets></p><p><offsets xml_i="30152" xml_f="30368" txt_i="16505" txt_f="16721">- If ERCP is not successful, the patient is to be referred to a tertiary centre for a second attempt for endoscopic drainage, or a percutaneous drainage will be performed, according to local preference and expertise.</offsets></p><p><offsets xml_i="30375" xml_f="30544" txt_i="16722" txt_f="16888">- Biliary drainage is considered adequate if a decrease of &gt; 50% of serum bilirubin level is found after two weeks of drainage; otherwise the stent should be changed.</offsets></p><p><offsets xml_i="30551" xml_f="30758" txt_i="16889" txt_f="17096">- After four weeks of PBD, patients will undergo surgery. In case of complications indicating inadequate bile drainage and stent obstruction (cholangitis, stent occlusion) a stent exchange will be performed.</offsets></p><p><offsets xml_i="30765" xml_f="30945" txt_i="17097" txt_f="17277">- Other complications, such as bleeding or severe pancreatitis, are treated according to the local generally accepted guidelines and could consequently lead to a delay of surgery [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="30977" xml_f="30979" txt_i="17277" txt_f="17279">35</offsets></xref><offsets xml_i="30986" xml_f="30987" txt_i="17279" txt_f="17280">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="31019" xml_f="31021" txt_i="17280" txt_f="17282">36</offsets></xref><offsets xml_i="31028" xml_f="31030" txt_i="17282" txt_f="17284">].</offsets></p><p></p></sec><sec><title><offsets xml_i="31059" xml_f="31066" txt_i="17287" txt_f="17294">Surgery</offsets></title><p><offsets xml_i="31077" xml_f="31322" txt_i="17295" txt_f="17534">- Surgery is planned keeping in mind the maximum estimated bilirubin level (&gt; 40 Î¼mol/l and &lt; 250 Î¼mol/l at randomization) must not exceed 300 Î¼mol/l, 24 hours before surgery (e.g. high bilirubin at randomization requires earlier surgery).</offsets></p><p><offsets xml_i="31329" xml_f="31609" txt_i="17535" txt_f="17815">- Vitamin K (10 mg, oral, 1 day preoperatively) is given on indication, cefuroxim (1500 mg, intravenous single shot, 1/2 hour preoperatively) and octreotide or analogues (3 Ã 100 Î¼g, subcutaneous, 12 hours before surgery and continued for seven days after surgery) as prophylaxis.</offsets></p><p><offsets xml_i="31616" xml_f="31821" txt_i="17816" txt_f="18021">- During exploration the standard procedure will be the standard pylorus preserving pancreatoduodenectomy (PPPD), as previously described, with removal of lymph nodes at the right side of the portal vein [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="31853" xml_f="31855" txt_i="18021" txt_f="18023">33</offsets></xref><offsets xml_i="31862" xml_f="32074" txt_i="18023" txt_f="18235">]. If indicated (suspicious ingrowth proximal duodenum/pylorus) a Whipple procedure is to be performed. In case of limited vascular ingrowth, a (wedge) resection of the portal/mesenteric vein might be performed [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="32106" xml_f="32108" txt_i="18235" txt_f="18237">33</offsets></xref><offsets xml_i="32115" xml_f="32116" txt_i="18237" txt_f="18238">,</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="32148" xml_f="32150" txt_i="18238" txt_f="18240">41</offsets></xref><offsets xml_i="32157" xml_f="32159" txt_i="18240" txt_f="18242">].</offsets></p><p><offsets xml_i="32166" xml_f="32268" txt_i="18243" txt_f="18345">- Reconstruction is performed by pancreaticojejunostomy, a hepaticojejunostomy and gastrojejunostomy [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="32300" xml_f="32302" txt_i="18345" txt_f="18347">33</offsets></xref><offsets xml_i="32309" xml_f="32311" txt_i="18347" txt_f="18349">].</offsets></p><p><offsets xml_i="32318" xml_f="32448" txt_i="18350" txt_f="18480">- One silicone drain is placed near the pancreaticojejunostomy and/or one near the hepaticojejunostomy; T-drains will not be used.</offsets></p><p><offsets xml_i="32455" xml_f="32518" txt_i="18481" txt_f="18544">- A feeding jejunostomy is not to be used as standard treatment</offsets></p><p><offsets xml_i="32525" xml_f="32649" txt_i="18545" txt_f="18669">- If resection is not performed due to metastases or local ingrowth, biopsies have to be taken for a histological diagnosis.</offsets></p><p><offsets xml_i="32656" xml_f="32764" txt_i="18670" txt_f="18778">Palliative treatment consist of a hepaticojejunostomy with gastroenterostomy plus a celiac plexus blockade [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="32795" xml_f="32796" txt_i="18778" txt_f="18779">7</offsets></xref><offsets xml_i="32803" xml_f="32804" txt_i="18779" txt_f="18780">,</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="32836" xml_f="32838" txt_i="18780" txt_f="18782">33</offsets></xref><offsets xml_i="32845" xml_f="32846" txt_i="18782" txt_f="18783">,</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="32878" xml_f="32880" txt_i="18783" txt_f="18785">42</offsets></xref><offsets xml_i="32887" xml_f="32989" txt_i="18785" txt_f="18887">]. If a hepaticojejunostomy is not possible, a Wallstent is inserted postoperatively by means of ERCP.</offsets></p></sec></sec><sec><title><offsets xml_i="33017" xml_f="33037" txt_i="18890" txt_f="18910">Statistical analysis</offsets></title><sec><title><offsets xml_i="33057" xml_f="33075" txt_i="18911" txt_f="18929">Intention to treat</offsets></title><p><offsets xml_i="33086" xml_f="33169" txt_i="18930" txt_f="19013">The analysis will be performed in accordance with the intention to treat principle.</offsets></p></sec><sec><title><offsets xml_i="33191" xml_f="33214" txt_i="19015" txt_f="19038">Sample size calculation</offsets></title><p><offsets xml_i="33225" xml_f="33489" txt_i="19039" txt_f="19303">The recently performed meta-analysis of randomized clinical trials and comparative studies, addressing the effectiveness of a PBD strategy in jaundiced patients versus a direct surgical treatment, did not show a difference in mortality between the two strategies [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="33521" xml_f="33523" txt_i="19303" txt_f="19305">37</offsets></xref><offsets xml_i="33530" xml_f="33685" txt_i="19305" txt_f="19460">]. The overall complication rates were, summarizing level I and II studies, 42% for the 'early surgery' strategy and 58.1% for strategy with preceding PBD.</offsets></p><p><offsets xml_i="33692" xml_f="34357" txt_i="19461" txt_f="20126">The sample size calculation is based on the equivalence design for the primary endpoint, severe complications of treatment. Based on an expected 38% complication rate for early surgical treatment and 48% for preoperative drainage, equivalence is taken to be demonstrated if the percentage of severe complications with early surgical treatment is not more than 10% higher compared to standard treatment with PBD. Accounting for a 10% dropout, 105 patients are needed in each arm resulting in a study population of 210 (alpha = 0.95, beta = 0.8). If equivalence is found, the comparison of the secondary outcomes will be essential in selecting the preferred strategy.</offsets></p></sec></sec><sec><title><offsets xml_i="34385" xml_f="34415" txt_i="20129" txt_f="20159">Data collection and monitoring</offsets></title><p><offsets xml_i="34426" xml_f="34922" txt_i="20160" txt_f="20656">All postoperative complications will be monitored during hospital stay and follow-up of 2, 6, 12 weeks after discharge. The questionnaires (QLQ-C30/PAN-26) are filled in by the patient on the day of randomization, after two weeks of drainage when randomized for PBD, and three and six weeks after discharge from admission for surgery. There will be regular contact between the trial coordinator and the participating centres. The trial coordinator will monitor the data of every included patient.</offsets></p></sec><sec><title><offsets xml_i="34944" xml_f="34957" txt_i="20658" txt_f="20671">Data analysis</offsets></title><p><offsets xml_i="34968" xml_f="35612" txt_i="20672" txt_f="21316">The study is designed as an equivalence trial with respect to the primary outcome measure and superiority with respect to the secondary outcome measures. The principal analysis consists of an intention-to-treat comparison of the severe complication rate in both treatment strategies. The comparison will be expressed in terms of a relative risk and 95% confidence intervals. The research hypothesis will be evaluated using a two-group large-sample normal approximation test of proportions, with a one-sided 0.05 significance level. In addition, a comparison of the incidence of complications over time will be made using Kaplan-Meier estimates.</offsets></p><p><offsets xml_i="35619" xml_f="36178" txt_i="21317" txt_f="21867">Subsequent analyses are directed at the secondary endpoints. The total number of additional procedures, the length of hospital stay, hospital-free survival and total costs will be compared using t-test statistics. Preplanned subgroup analyses include type of surgery (resection versus bypass), severity of jaundice and other risk factors for complications such as age &gt; 70 years, weight loss &gt; 10%, low albumin levels, renal function, low Hb (&lt; 7 mmol/l), tumor pathology (papilla neoplasms, pancreatic head neoplasms and distal bile duct neoplasms).</offsets></p><p><offsets xml_i="36185" xml_f="36939" txt_i="21868" txt_f="22619">An independent safety committee, consisting of three specialists (dept of internal medicine, dept of surgery, dept of clinical statistics), will guarantee the safety of the patients. After 105 included patients (50%), a blinded interim-analysis will be performed of all endpoints. Because of the delayed response for determination of the primary endpoint (severe complications), this analysis will be performed 120 days after randomization of the last patient to reach n: 105. The nominal significance (sequential two-sided testing) for the stopping rule is p &lt; 0.01 (Î± = 0.01) for adverse effects (severe complications principal endpoint of safety analysis). Analysis will be performed for the individual groups and for the principal adverse effects.</offsets></p></sec><sec><title><offsets xml_i="36961" xml_f="36980" txt_i="22621" txt_f="22640">Economic evaluation</offsets></title><p><offsets xml_i="36991" xml_f="37269" txt_i="22641" txt_f="22919">If the assumption of equivalence holds, the economic evaluation can be designed as a cost-minimization analysis from a societal perspective. Given equivalence in survival for the two strategies, the time horizon for the evaluation can be limited to 120 days after randomization.</offsets></p><p><offsets xml_i="37276" xml_f="37649" txt_i="22920" txt_f="23293">According to guidelines for cost research, the two treatment strategies will be compared from the societal perspective, regarding direct medical and non-medical and indirect non-medical costs. In the economic evaluation direct medical and non-medical costs and indirect costs are related to the primary endpoints, reflecting economic efficiency at 3 months after admission.</offsets></p><p><offsets xml_i="37656" xml_f="38237" txt_i="23294" txt_f="23875">We expect early surgery without preoperative biliary drainage to lead to a shorter hospital stay, less invasive diagnostic tests, fewer additional procedures and, hence, lower costs. Nowadays overall mortality after PD is around 2% for control patients (drainage) and therefore an increase or reduction of mortality can only have limited influence on the primary outcome parameter (severe complications and death). As we could not find any data to provide even an indication of economic outcomes of both strategies, the evaluation will be designed as a cost-effectiveness analysis.</offsets></p><p><offsets xml_i="38244" xml_f="38985" txt_i="23876" txt_f="24617">To document cumulative three-month total costs for both treatment strategies, we will track the use of resources, using hospital information systems and additional data collection in the case record forms. The tracking of resources will start at randomization (i.e. after preoperative staging has been completed). Unit prices will either be determined based on current guidelines for economic evaluations or, alternatively, if not existent or not applicable, they will be calculated during the study. Out of hospital resource use, as well as data on direct non-medical and indirect costs will not be analyzed. Within the study, differences in treatment will be analyzed to detect potential limitations to the reproducibility of our findings.</offsets></p></sec></sec><sec><title><offsets xml_i="39013" xml_f="39023" txt_i="24620" txt_f="24630">Discussion</offsets></title><p><offsets xml_i="39034" xml_f="40059" txt_i="24631" txt_f="25656">The concept of PBD has been developed to reduce the postoperative morbidity and mortality in patients with obstructive jaundice, caused by a suspected pancreatic/periampullary malignancy. However, PBD, both endoscopic or percutaneous, is associated with an increased incidence of postoperative morbidity [mostly infectious complications] and postoperative mortality when performed prior to a pancreatoduodenectomy. Furthermore, the techniques used for PBD harbour their own complications. Therefore, the overall conclusion not to routinely perform preoperative biliary drainage seems evident. Nevertheless, still the majority of these patients undergo preoperative drainage, often preceded by a diagnostic endoscopic retrograde cholangiopancreatography (ERCP). Unfortunately, most of the available literature addressing the efficacy of PBD suffers from methodological flaws (e.g. differences in drainage procedures, duration of drainage, internal vs. external drainage, surgical procedures, small sample size) or is outdated.</offsets></p><p><offsets xml_i="40066" xml_f="40497" txt_i="25657" txt_f="26088">Therefore, a prospective randomized trial addressing the effects of PBD, and thus solving the longstanding controversy whether or not PBD should be routinely performed in jaundiced patients prior to a pancreatoduodenectomy, is indicated. Especially, for the potential consequences of future treatment might be considerable; a shorter workup period, less invasive diagnostic procedures (ERCP) and a shorter time interval to surgery.</offsets></p></sec><sec><title><offsets xml_i="40519" xml_f="40532" txt_i="26090" txt_f="26103">Abbreviations</offsets></title><p><offsets xml_i="40543" xml_f="40586" txt_i="26104" txt_f="26147">DROP-trial: DRainage vs. (direct) Operation</offsets></p><p><offsets xml_i="40593" xml_f="40627" txt_i="26148" txt_f="26182">PBD: preoperative biliary drainage</offsets></p><p><offsets xml_i="40634" xml_f="40686" txt_i="26183" txt_f="26235">ERCP: endoscopic retrograde cholangiopancreatography</offsets></p><p><offsets xml_i="40693" xml_f="40809" txt_i="26236" txt_f="26352">EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C-30</offsets></p><p><offsets xml_i="40816" xml_f="40941" txt_i="26353" txt_f="26478">EORTC QLQ-PAN26: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire PANcreas-26</offsets></p></sec><sec><title><offsets xml_i="40963" xml_f="40982" txt_i="26480" txt_f="26499">Competing interests</offsets></title><p><offsets xml_i="40993" xml_f="41053" txt_i="26500" txt_f="26560">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="41075" xml_f="41097" txt_i="26562" txt_f="26584">Authors' contributions</offsets></title><p><offsets xml_i="41108" xml_f="41550" txt_i="26585" txt_f="27027">NAvdG and SMMC drafted the manuscript. DJG is the principal investigator of this study and co-authored the writing of the manuscript. PMMB, OMD, CHJE, EJK, JJGMG, JWG, EJH, JHGK, CJHML, LTW, MJB EAJW participated in the design of the study during several meetings and are local investigators at the participating centres. The other authors are local investigators. All authors edited the manuscript and read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="41572" xml_f="41595" txt_i="27029" txt_f="27052">Pre-publication history</offsets></title><p><offsets xml_i="41606" xml_f="41670" txt_i="27053" txt_f="27117">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2482/7/3/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>ZonMw, grant number 945-03-015</p><p>All authors are member of the DROP-study group.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><article-title>Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas</article-title><source>Gut</source><year>2005</year><volume>54 Suppl 5</volume><fpage>v1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15888770</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Groen</surname><given-names>PC</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>LaRusso</surname><given-names>NF</given-names></name><name><surname>Gunderson</surname><given-names>LL</given-names></name><name><surname>Nagorney</surname><given-names>DM</given-names></name></person-group><article-title>Biliary tract cancers</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1368</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">10536130</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199910283411807</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phoa</surname><given-names>SS</given-names></name><name><surname>Reeders</surname><given-names>JW</given-names></name><name><surname>Rauws</surname><given-names>EA</given-names></name><name><surname>De</surname><given-names>WL</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Lameris</surname><given-names>JS</given-names></name></person-group><article-title>Spiral computed tomography for preoperative staging of potentially resectable carcinoma of the pancreatic head</article-title><source>Br J Surg</source><year>1999</year><volume>86</volume><fpage>789</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">10383580</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2168.1999.01138.x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>DM</given-names></name><name><surname>Delbeke</surname><given-names>D</given-names></name><name><surname>Beauchamp</surname><given-names>RD</given-names></name><name><surname>Chapman</surname><given-names>WC</given-names></name><name><surname>Sandler</surname><given-names>MP</given-names></name><name><surname>Sharp</surname><given-names>KW</given-names></name><name><surname>Richards</surname><given-names>WO</given-names></name><name><surname>Wright</surname><given-names>JK</given-names></name><name><surname>Frexes</surname><given-names>ME</given-names></name><name><surname>Pinson</surname><given-names>CW</given-names></name><name><surname>Leach</surname><given-names>SD</given-names></name></person-group><article-title>18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer</article-title><source>Ann Surg</source><year>1999</year><volume>229</volume><fpage>729</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">10235532</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199905000-00016</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>van Geenen</surname><given-names>RC</given-names></name><name><surname>van Gulik</surname><given-names>TM</given-names></name><name><surname>de Haan</surname><given-names>RJ</given-names></name><name><surname>de Wit</surname><given-names>LT</given-names></name><name><surname>Busch</surname><given-names>OR</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name></person-group><article-title>Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume</article-title><source>Ann Surg</source><year>2000</year><volume>232</volume><fpage>786</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">11088073</pub-id><pub-id pub-id-type="doi">10.1097/00000658-200012000-00007</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balcom</surname><given-names>JH</given-names></name><name><surname>Rattner</surname><given-names>DW</given-names></name><name><surname>Warshaw</surname><given-names>AL</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Fernandez-del</surname><given-names>CC</given-names></name></person-group><article-title>Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization</article-title><source>Arch Surg</source><year>2001</year><volume>136</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">11296108</pub-id><pub-id pub-id-type="doi">10.1001/archsurg.136.4.391</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Heek</surname><given-names>NT</given-names></name><name><surname>de Castro</surname><given-names>SM</given-names></name><name><surname>van Eijck</surname><given-names>CH</given-names></name><name><surname>van Geenen</surname><given-names>RC</given-names></name><name><surname>Hesselink</surname><given-names>EJ</given-names></name><name><surname>Breslau</surname><given-names>PJ</given-names></name><name><surname>Tran</surname><given-names>TC</given-names></name><name><surname>Kazemier</surname><given-names>G</given-names></name><name><surname>Visser</surname><given-names>MR</given-names></name><name><surname>Busch</surname><given-names>OR</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life</article-title><source>Ann Surg</source><year>2003</year><volume>238</volume><fpage>894</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">14631226</pub-id><pub-id pub-id-type="doi">10.1097/01.sla.0000098617.21801.95</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Wagensveld</surname><given-names>BA</given-names></name><name><surname>Coene</surname><given-names>PP</given-names></name><name><surname>van Gulik</surname><given-names>TM</given-names></name><name><surname>Rauws</surname><given-names>EA</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>Outcome of palliative biliary and gastric bypass surgery for pancreatic head carcinoma in 126 patients</article-title><source>Br J Surg</source><year>1997</year><volume>84</volume><fpage>1402</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">9361599</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800841018</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>HA</given-names></name><name><surname>Cameron</surname><given-names>JL</given-names></name><name><surname>Postier</surname><given-names>RG</given-names></name><name><surname>Gadacz</surname><given-names>TR</given-names></name></person-group><article-title>Factors affecting mortality in biliary tract surgery</article-title><source>Am J Surg</source><year>1981</year><volume>141</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">6970004</pub-id><pub-id pub-id-type="doi">10.1016/0002-9610(81)90014-3</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>CP</given-names></name><name><surname>Dixon</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>TV</given-names></name><name><surname>Davies</surname><given-names>GC</given-names></name></person-group><article-title>Surgical experience of deeply jaundiced patients with bile duct obstruction</article-title><source>Br J Surg</source><year>1984</year><volume>71</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">6607760</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800710326</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname><given-names>JD</given-names></name><name><surname>Krukowski</surname><given-names>ZH</given-names></name><name><surname>Matheson</surname><given-names>NA</given-names></name></person-group><article-title>Surgical morbidity and mortality in one hundred and twenty-nine patients with obstructive jaundice</article-title><source>Br J Surg</source><year>1988</year><volume>75</volume><fpage>216</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">3349328</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800750309</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whipple</surname><given-names>AO</given-names></name><name><surname>Parsons</surname><given-names>WB</given-names></name><name><surname>Mullins</surname><given-names>CR</given-names></name></person-group><article-title>Treatment of carcinoma of the ampulla of Vater</article-title><source>Ann Surg</source><year>1935</year><volume>102</volume><fpage>763</fpage><lpage>779</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Coelho</surname><given-names>JC</given-names></name><name><surname>Fisher</surname><given-names>JD</given-names></name><name><surname>Schlegel</surname><given-names>JF</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Moody</surname><given-names>FG</given-names></name></person-group><article-title>Endotoxemia after relief of biliary obstruction by internal and external drainage in rats</article-title><source>Am J Surg</source><year>1986</year><volume>151</volume><fpage>476</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">3515981</pub-id><pub-id pub-id-type="doi">10.1016/0002-9610(86)90107-8</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roughneen</surname><given-names>PT</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Kulkarni</surname><given-names>AD</given-names></name><name><surname>Fanslow</surname><given-names>WF</given-names></name><name><surname>Rowlands</surname><given-names>BJ</given-names></name></person-group><article-title>Impaired specific cell-mediated immunity in experimental biliary obstruction and its reversibility by internal biliary drainage</article-title><source>J Surg Res</source><year>1986</year><volume>41</volume><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">3762122</pub-id><pub-id pub-id-type="doi">10.1016/0022-4804(86)90016-8</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Roughneen</surname><given-names>PT</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Moody</surname><given-names>FG</given-names></name><name><surname>Rowlands</surname><given-names>BJ</given-names></name></person-group><article-title>Changes in nutritional status associated with obstructive jaundice and biliary drainage in rats</article-title><source>Am J Clin Nutr</source><year>1986</year><volume>44</volume><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">3751957</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Coelho</surname><given-names>JC</given-names></name><name><surname>Schlegel</surname><given-names>JF</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Moody</surname><given-names>FG</given-names></name></person-group><article-title>The effect of preoperative internal and external biliary drainage on mortality of jaundiced rats</article-title><source>Arch Surg</source><year>1987</year><volume>122</volume><fpage>731</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">3579589</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greve</surname><given-names>JW</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name></person-group><article-title>Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study</article-title><source>Hepatology</source><year>1989</year><volume>10</volume><fpage>454</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">2777206</pub-id><pub-id pub-id-type="doi">10.1002/hep.1840100409</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greve</surname><given-names>JW</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>von Leeuwen</surname><given-names>PA</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name></person-group><article-title>Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study</article-title><source>Gut</source><year>1990</year><volume>31</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">2311978</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greve</surname><given-names>JW</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Soeters</surname><given-names>PB</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name></person-group><article-title>Suppression of cellular immunity in obstructive jaundice is caused by endotoxins: a study with germ-free rats</article-title><source>Gastroenterology</source><year>1990</year><volume>98</volume><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">2295404</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bemelmans</surname><given-names>MH</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Greve</surname><given-names>JW</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name></person-group><article-title>Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice</article-title><source>Hepatology</source><year>1992</year><volume>15</volume><fpage>1132</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">1592352</pub-id><pub-id pub-id-type="doi">10.1002/hep.1840150626</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bemelmans</surname><given-names>MH</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Greve</surname><given-names>JW</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name></person-group><article-title>Effect of antitumour necrosis factor treatment on circulating tumour necrosis factor levels and mortality after surgery in jaundiced mice</article-title><source>Br J Surg</source><year>1993</year><volume>80</volume><fpage>1055</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">8402066</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800800845</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Moody</surname><given-names>FG</given-names></name></person-group><article-title>Preoperative percutaneous transhepatic drainage: use or abuse. A clinical review</article-title><source>Surg Gastroenterol</source><year>1984</year><volume>3</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">6443719</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>GA</given-names></name><name><surname>Benjamin</surname><given-names>IS</given-names></name><name><surname>Hodgson</surname><given-names>HJ</given-names></name><name><surname>Bowley</surname><given-names>NB</given-names></name><name><surname>Allison</surname><given-names>DJ</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name></person-group><article-title>Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial</article-title><source>Br J Surg</source><year>1984</year><volume>71</volume><fpage>371</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">6372935</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800710522</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>HA</given-names></name><name><surname>Gomes</surname><given-names>AS</given-names></name><name><surname>Lois</surname><given-names>JF</given-names></name><name><surname>Mann</surname><given-names>LL</given-names></name><name><surname>Deutsch</surname><given-names>LS</given-names></name><name><surname>Longmire</surname><given-names>WP</given-names><suffix>Jr.</suffix></name></person-group><article-title>Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?</article-title><source>Ann Surg</source><year>1985</year><volume>201</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">2986562</pub-id><pub-id pub-id-type="doi">10.1097/00000658-198505000-00002</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hatfield</surname><given-names>AR</given-names></name><name><surname>Tobias</surname><given-names>R</given-names></name><name><surname>Terblanche</surname><given-names>J</given-names></name><name><surname>Girdwood</surname><given-names>AH</given-names></name><name><surname>Fataar</surname><given-names>S</given-names></name><name><surname>Harries-Jones</surname><given-names>R</given-names></name><name><surname>Kernoff</surname><given-names>L</given-names></name><name><surname>Marks</surname><given-names>IN</given-names></name></person-group><article-title>Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial</article-title><source>Lancet</source><year>1982</year><volume>2</volume><fpage>896</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">6126752</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(82)90866-2</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>EC</given-names></name><name><surname>Mok</surname><given-names>FP</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name><name><surname>Lo</surname><given-names>CM</given-names></name><name><surname>Chu</surname><given-names>KM</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><article-title>Preoperative endoscopic drainage for malignant obstructive jaundice</article-title><source>Br J Surg</source><year>1994</year><volume>81</volume><fpage>1195</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">7741850</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800810839</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RC</given-names></name><name><surname>Pooley</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>CR</given-names></name><name><surname>Faithful</surname><given-names>GR</given-names></name></person-group><article-title>Preoperative percutaneous transhepatic internal drainage in obstructive jaundice: a randomized, controlled trial examining renal function</article-title><source>Surgery</source><year>1985</year><volume>97</volume><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">3890241</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karsten</surname><given-names>TM</given-names></name><name><surname>Allema</surname><given-names>JH</given-names></name><name><surname>Reinders</surname><given-names>M</given-names></name><name><surname>van Gulik</surname><given-names>TM</given-names></name><name><surname>de Wit</surname><given-names>LT</given-names></name><name><surname>Verbeek</surname><given-names>PC</given-names></name><name><surname>Huibregtse</surname><given-names>K</given-names></name><name><surname>Tytgat</surname><given-names>GN</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>Preoperative biliary drainage, colonisation of bile and postoperative complications in patients with tumours of the pancreatic head: a retrospective analysis of 241 consecutive patients</article-title><source>Eur J Surg</source><year>1996</year><volume>162</volume><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">8956957</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sewnath</surname><given-names>ME</given-names></name><name><surname>Birjmohun</surname><given-names>RS</given-names></name><name><surname>Rauws</surname><given-names>EA</given-names></name><name><surname>Huibregtse</surname><given-names>K</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy</article-title><source>J Am Coll Surg</source><year>2001</year><volume>192</volume><fpage>726</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">11400966</pub-id><pub-id pub-id-type="doi">10.1016/S1072-7515(01)00819-5</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>TA</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Cameron</surname><given-names>JL</given-names></name><name><surname>Pitt</surname><given-names>HA</given-names></name><name><surname>Lillemoe</surname><given-names>KD</given-names></name></person-group><article-title>Do preoperative biliary stents increase postpancreaticoduodenectomy complications?</article-title><source>J Gastrointest Surg</source><year>2000</year><volume>4</volume><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">10769088</pub-id><pub-id pub-id-type="doi">10.1016/S1091-255X(00)80074-8</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Povoski</surname><given-names>SP</given-names></name><name><surname>Karpeh</surname><given-names>MS</given-names><suffix>Jr.</suffix></name><name><surname>Conlon</surname><given-names>KC</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name></person-group><article-title>Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy</article-title><source>Ann Surg</source><year>1999</year><volume>230</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">10450725</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199908000-00001</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lillemoe</surname><given-names>KD</given-names></name></person-group><article-title>Preoperative biliary drainage and surgical outcome</article-title><source>Ann Surg</source><year>1999</year><volume>230</volume><fpage>143</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">10450726</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199908000-00002</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Nieveen van Dijkum</surname><given-names>EJ</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name></person-group><article-title>The standard diagnostic work-up and surgical treatment of pancreatic head tumours</article-title><source>Eur J Surg Oncol</source><year>1999</year><volume>25</volume><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">10218451</pub-id><pub-id pub-id-type="doi">10.1053/ejso.1998.0612</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieveen van Dijkum</surname><given-names>EJ</given-names></name><name><surname>Romijn</surname><given-names>MG</given-names></name><name><surname>Terwee</surname><given-names>CB</given-names></name><name><surname>de Wit</surname><given-names>LT</given-names></name><name><surname>van der Meulen</surname><given-names>JH</given-names></name><name><surname>Lameris</surname><given-names>HS</given-names></name><name><surname>Rauws</surname><given-names>EA</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>van Eyck</surname><given-names>CH</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma</article-title><source>Ann Surg</source><year>2003</year><volume>237</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">12496532</pub-id><pub-id pub-id-type="doi">10.1097/00000658-200301000-00010</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huibregtse</surname><given-names>K</given-names></name></person-group><article-title>Complications of endoscopic sphincterotomy and their prevention</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>961</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">8782505</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199609263351309</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cotton</surname><given-names>PB</given-names></name><name><surname>Lehman</surname><given-names>G</given-names></name><name><surname>Vennes</surname><given-names>J</given-names></name><name><surname>Geenen</surname><given-names>JE</given-names></name><name><surname>Russell</surname><given-names>RC</given-names></name><name><surname>Meyers</surname><given-names>WC</given-names></name><name><surname>Liguory</surname><given-names>C</given-names></name><name><surname>Nickl</surname><given-names>N</given-names></name></person-group><article-title>Endoscopic sphincterotomy complications and their management: an attempt at consensus</article-title><source>Gastrointest Endosc</source><year>1991</year><volume>37</volume><fpage>383</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">2070995</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sewnath</surname><given-names>ME</given-names></name><name><surname>Karsten</surname><given-names>TM</given-names></name><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>Rauws</surname><given-names>EJ</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice</article-title><source>Ann Surg</source><year>2002</year><volume>236</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">12131081</pub-id><pub-id pub-id-type="doi">10.1097/00000658-200207000-00005</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Berge Henegouwen</surname><given-names>MI</given-names></name><name><surname>van Gulik</surname><given-names>TM</given-names></name><name><surname>Akkermans</surname><given-names>LM</given-names></name><name><surname>Jansen</surname><given-names>JB</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers</article-title><source>Gut</source><year>1997</year><volume>41</volume><fpage>758</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">9471423</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimmings</surname><given-names>AN</given-names></name><name><surname>Van Deventer</surname><given-names>SJ</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Rauws</surname><given-names>EA</given-names></name><name><surname>Huibregtse</surname><given-names>K</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage</article-title><source>Gut</source><year>2000</year><volume>46</volume><fpage>725</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">10764720</pub-id><pub-id pub-id-type="doi">10.1136/gut.46.5.725</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzsimmons</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Sandberg</surname><given-names>AA</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Beger</surname><given-names>HG</given-names></name><name><surname>Birk</surname><given-names>D</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><name><surname>Fernandez</surname><given-names>CL</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Grahm</surname><given-names>AL</given-names></name><name><surname>Jeekel</surname><given-names>J</given-names></name><name><surname>Laugier</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Singer</surname><given-names>MW</given-names></name><name><surname>Tihanyi</surname><given-names>T</given-names></name></person-group><article-title>Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>939</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">10533475</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00047-7</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allema</surname><given-names>JH</given-names></name><name><surname>Reinders</surname><given-names>ME</given-names></name><name><surname>van Gulik</surname><given-names>TM</given-names></name><name><surname>Van Leeuwen</surname><given-names>DJ</given-names></name><name><surname>de Wit</surname><given-names>LT</given-names></name><name><surname>Verbeek</surname><given-names>PC</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head</article-title><source>Br J Surg</source><year>1994</year><volume>81</volume><fpage>1642</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">7827892</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800811126</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lillemoe</surname><given-names>KD</given-names></name><name><surname>Cameron</surname><given-names>JL</given-names></name><name><surname>Kaufman</surname><given-names>HS</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Pitt</surname><given-names>HA</given-names></name><name><surname>Sauter</surname><given-names>PK</given-names></name></person-group><article-title>Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial</article-title><source>Ann Surg</source><year>1993</year><volume>217</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">7683868</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199305010-00004</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><name><surname>Butturini</surname><given-names>G</given-names></name><name><surname>Fingerhut</surname><given-names>A</given-names></name><name><surname>Yeo</surname><given-names>C</given-names></name><name><surname>Izbicki</surname><given-names>J</given-names></name><name><surname>Neoptolemos</surname><given-names>J</given-names></name><name><surname>Sarr</surname><given-names>M</given-names></name><name><surname>Traverso</surname><given-names>W</given-names></name><name><surname>Buchler</surname><given-names>M</given-names></name></person-group><article-title>Postoperative pancreatic fistula: an international study group (ISGPF) definition</article-title><source>Surgery</source><year>2005</year><volume>138</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16003309</pub-id><pub-id pub-id-type="doi">10.1016/j.surg.2005.05.001</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Castro</surname><given-names>SM</given-names></name><name><surname>Kuhlmann</surname><given-names>KF</given-names></name><name><surname>Busch</surname><given-names>OR</given-names></name><name><surname>van Delden</surname><given-names>OM</given-names></name><name><surname>Lameris</surname><given-names>JS</given-names></name><name><surname>van Gulik</surname><given-names>TM</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name></person-group><article-title>Delayed massive hemorrhage after pancreatic and biliary surgery: embolization or surgery?</article-title><source>Ann Surg</source><year>2005</year><volume>241</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15621995</pub-id></citation></ref></ref-list></back></article>